Baxter International Inc.

NYSE:BAX Stock Report

Market Cap: US$12.6b

Baxter International Past Earnings Performance

Past criteria checks 0/6

Baxter International's earnings have been declining at an average annual rate of -30.2%, while the Medical Equipment industry saw earnings growing at 13.3% annually. Revenues have been declining at an average rate of 3.1% per year.

Key information

-30.17%

Earnings growth rate

-30.05%

EPS growth rate

Medical Equipment Industry Growth8.90%
Revenue growth rate-3.13%
Return on equity-3.30%
Net Margin-2.27%
Last Earnings Update30 Jun 2025

Recent past performance updates

Recent updates

Baxter: Margin-Focused Model Faces Growth Constraints

Jul 18

Baxter International Inc.'s (NYSE:BAX) Shares Lagging The Industry But So Is The Business

Jun 21
Baxter International Inc.'s (NYSE:BAX) Shares Lagging The Industry But So Is The Business

Here's Why Baxter International (NYSE:BAX) Has A Meaningful Debt Burden

May 02
Here's Why Baxter International (NYSE:BAX) Has A Meaningful Debt Burden

Baxter: Messy, Yet Appealing, If New Management Can Deliver

Apr 21

Baxter International (NYSE:BAX) Will Pay A Dividend Of $0.17

Feb 21
Baxter International (NYSE:BAX) Will Pay A Dividend Of $0.17

Baxter International: An Uncompelling Investment With High Debt

Jan 31

Does Baxter International (NYSE:BAX) Have A Healthy Balance Sheet?

Jan 27
Does Baxter International (NYSE:BAX) Have A Healthy Balance Sheet?

Is Baxter International Inc. (NYSE:BAX) Trading At A 49% Discount?

Sep 05
Is Baxter International Inc. (NYSE:BAX) Trading At A 49% Discount?

Baxter- Reiterating Our Buy Rating After A Promising Q2

Aug 07

Baxter: Why Investors Should Take Advantage Of The Low Valuation

Jul 16

Baxter International: Shares Too Cheap, EPS Growth Ahead With A Possible Spinoff

May 08

Broyhill - Baxter International: Renal Care Spin-Off And Recent Revamp Should Provide Catalysts

Feb 23

Baxter International: A Cheap Big Pharma Stock With Improving Earnings And +3% Dividend Yield

Dec 12

Should You Buy Baxter Or DaVita After The Fallout From The Ozempic Trial?

Oct 12

Dividend Challengers Review: Baxter International

Aug 14

Revenue & Expenses Breakdown

How Baxter International makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NYSE:BAX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2510,887-2472,761532
31 Mar 2510,771-2772,777528
31 Dec 2410,636-3372,824510
30 Sep 2410,6093712,659506
30 Jun 2410,5093482,623506
31 Mar 249,3371792,551471
31 Dec 2310,3601742,735508
30 Sep 2311,379962,907537
30 Jun 2312,389-2,9323,103555
31 Mar 2314,461-2,6733,489608
31 Dec 2210,057-3,1252,811447
30 Sep 2214,275-2,5683,435580
30 Jun 2213,8928763,212562
31 Mar 2213,3969922,957553
31 Dec 2112,1461,0222,605530
30 Sep 2112,4511,2142,530528
30 Jun 2112,1971,1202,460521
31 Mar 2111,8171,0682,370499
31 Dec 2011,6731,1022,405519
30 Sep 2011,5319112,360516
30 Jun 2011,4109242,383528
31 Mar 2011,5269912,414552
31 Dec 1911,3621,0012,442561
30 Sep 1911,1561,3352,348554
30 Jun 1911,0661,4842,359573
31 Mar 1911,0601,5052,399595
31 Dec 1811,0991,5522,401618
30 Sep 1811,0631,0652,527636
30 Jun 1811,0097952,572632
31 Mar 1810,7638402,478621
31 Dec 1710,5846092,516615
30 Sep 1710,4321,0252,424584
30 Jun 1710,2839042,382564
31 Mar 1710,2631,8522,447560
31 Dec 1610,1634,9662,520566
30 Sep 1610,1214,9092,566573
30 Jun 1610,0504,7842,625584
31 Mar 169,9403,6462,704582
31 Dec 159,9683932,832589
30 Sep 1510,1543372,972585
30 Jun 1510,3765103,087593
31 Mar 159,274843,037473
31 Dec 1410,7194573,182608
30 Sep 1412,2527393,301743

Quality Earnings: BAX is currently unprofitable.

Growing Profit Margin: BAX is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BAX is unprofitable, and losses have increased over the past 5 years at a rate of 30.2% per year.

Accelerating Growth: Unable to compare BAX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BAX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16%).

Return on Equity

High ROE: BAX has a negative Return on Equity (-3.3%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/08/24 21:46
End of Day Share Price 2025/08/22 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Baxter International Inc. is covered by 47 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Benjamin YeohAtlantic Equities LLP
Daniel OwczarskiAvondale Partners